secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rapport Therapeutics, Inc. (RAPP)
CIK:        0002012593
Form:       8-K
Filed at:   2026-04-21T23:59:59+00:00
Accession:  0001193125-26-167078
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

RAP-219 Phase 2a follow-up shows sustained seizure reduction; half-life updated to ~22 days
--------------------------------------------------------------------------------

- 90% median reduction in clinical seizures in weeks 9-12; 59% in weeks 13-16, demonstrating sustained effect after treatment cessation.
- Updated half-life of ~22 days (prior 14 days) with plasma concentrations maintaining >75% receptor occupancy through week 12.
- Two Phase 3 FOS trials (FOCUS 1 & 2) expected to start Q2 2026; open-label extension ongoing with initial data H2 2026.
- RAP-219 well tolerated; 2 mild treatment-related AEs, 3 SAEs unrelated to drug. Phase 2 bipolar mania topline expected H1 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2012593/000119312526167078/0001193125-26-167078-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2012593/000119312526167078/rapp-20260421.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-167078

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer